Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Michael J. Byrne"'
Autor:
Michael J. Byrne, Daniel Nuzum
Publikováno v:
Health and Social Care Chaplaincy. 8:206-217
COVID-19 has posed immense challenges for society in general, and for those who work in healthcare in particular. The impact and burden of pandemic isolation on the emotional and physical welfare of patients and staff is well documented. Healthcare s
Autor:
Michael J. Byrne
Publikováno v:
Open-File Report.
Autor:
Michael J. Byrne, Mark R. Dickman
Publikováno v:
Open-File Report.
Autor:
Michael J. Byrne
Publikováno v:
Open-File Report.
Publikováno v:
Open-File Report.
Publikováno v:
Journal of Thoracic Oncology. 9(8):1187-1194
Introduction Single time-point unidimensional tumor thickness measurements define measurable disease for clinical trial inclusion and also constitute a field in the International Association for the Study of Lung Cancer prospective mesothelioma stagi
Autor:
Ji H. Shin, Michael J. Byrne
Publikováno v:
Journal of Geotechnical and Geoenvironmental Engineering. 139:1837-1840
Autor:
Lucille Wood, Jean Firth, Peter Jacobs, David Marais, Michael J. Byrne, Renee Blewett, Graham Jackson
Publikováno v:
Hematology (Amsterdam, Netherlands). 2(6)
Patients with homozygous hypeicholesterolaemia are notoriously refractory to pharmacologic intervention, leaving regular long-term plasmapheresis as one of the most effective forms of therapy. In this situation we noted the universal development of a
Autor:
Lisa Paksec, Guy van Hazel, Diana Zannino, Bernie Fitzharris, Akiko Fong, Alan S. Coates, John F. Forbes, V J Harvey, Nicholas Wilcken, Peter Grimison, Val Gebski, Anna K. Nowak, Michael J. Byrne, T. Sourjina, Martin R. Stockler, Stephen P. Ackland, Prudence A. Francis, M. Corona Gainford, R. John Simes
Publikováno v:
Journal of Clinical Oncology. 29:4498-4504
Purpose We compared oral capecitabine, administered intermittently or continuously, versus classical cyclophosphamide, methotrexate, and fluorouracil (CMF) as first-line chemotherapy for women with advanced breast cancer unsuited to more intensive re